Logo image of BCDA

BIOCARDIA INC (BCDA) Stock Fundamental Analysis

NASDAQ:BCDA - Nasdaq - US09060U6064 - Common Stock - Currency: USD

2.31  -0.11 (-4.55%)

Fundamental Rating

2

BCDA gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 572 industry peers in the Biotechnology industry. The financial health of BCDA is average, but there are quite some concerns on its profitability. BCDA is quite expensive at the moment. It does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

BCDA had negative earnings in the past year.
BCDA had a negative operating cash flow in the past year.
BCDA had negative earnings in each of the past 5 years.
In the past 5 years BCDA always reported negative operating cash flow.
BCDA Yearly Net Income VS EBIT VS OCF VS FCFBCDA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 -5M -10M -15M

1.2 Ratios

With a Return On Assets value of -123.22%, BCDA is not doing good in the industry: 80.64% of the companies in the same industry are doing better.
BCDA has a Return On Equity of -280.49%. This is in the lower half of the industry: BCDA underperforms 74.25% of its industry peers.
Industry RankSector Rank
ROA -123.22%
ROE -280.49%
ROIC N/A
ROA(3y)-196.44%
ROA(5y)-168.98%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
BCDA Yearly ROA, ROE, ROICBCDA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 500 -500 1K

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for BCDA so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
BCDA Yearly Profit, Operating, Gross MarginsBCDA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 -2K -4K -6K -8K -10K

More info and screens

5

2. Health

2.1 Basic Checks

BCDA does not have a ROIC to compare to the WACC, probably because it is not profitable.
BCDA has less shares outstanding than it did 1 year ago.
The number of shares outstanding for BCDA has been reduced compared to 5 years ago.
There is no outstanding debt for BCDA. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
BCDA Yearly Shares OutstandingBCDA Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 5M 10M 15M 20M
BCDA Yearly Total Debt VS Total AssetsBCDA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 5M 10M 15M 20M

2.2 Solvency

Based on the Altman-Z score of -37.10, we must say that BCDA is in the distress zone and has some risk of bankruptcy.
BCDA has a Altman-Z score of -37.10. This is amonst the worse of the industry: BCDA underperforms 92.54% of its industry peers.
BCDA has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -37.1
ROIC/WACCN/A
WACC9.44%
BCDA Yearly LT Debt VS Equity VS FCFBCDA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 10M -10M 20M

2.3 Liquidity

BCDA has a Current Ratio of 1.78. This is a normal value and indicates that BCDA is financially healthy and should not expect problems in meeting its short term obligations.
The Current ratio of BCDA (1.78) is worse than 79.40% of its industry peers.
BCDA has a Quick Ratio of 1.78. This is a normal value and indicates that BCDA is financially healthy and should not expect problems in meeting its short term obligations.
BCDA has a Quick ratio of 1.78. This is in the lower half of the industry: BCDA underperforms 77.98% of its industry peers.
Industry RankSector Rank
Current Ratio 1.78
Quick Ratio 1.78
BCDA Yearly Current Assets VS Current LiabilitesBCDA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 5M 10M 15M 20M

More info and screens

4

3. Growth

3.1 Past

The Earnings Per Share has grown by an nice 17.91% over the past year.
The Revenue for BCDA has decreased by -87.54% in the past year. This is quite bad
BCDA shows a decrease in Revenue. Measured over the last years, the Revenue has been decreasing by -5.41% yearly.
EPS 1Y (TTM)17.91%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%66.11%
Revenue 1Y (TTM)-87.54%
Revenue growth 3Y47.05%
Revenue growth 5Y-5.41%
Sales Q2Q%-100%

3.2 Future

The Earnings Per Share is expected to grow by 13.37% on average over the next years. This is quite good.
Based on estimates for the next years, BCDA will show a very strong growth in Revenue. The Revenue will grow by 70.56% on average per year.
EPS Next Y61.55%
EPS Next 2Y35.57%
EPS Next 3Y22.21%
EPS Next 5Y13.37%
Revenue Next Year-84.28%
Revenue Next 2Y-70.69%
Revenue Next 3Y-55.88%
Revenue Next 5Y70.56%

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
BCDA Yearly Revenue VS EstimatesBCDA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2M 4M 6M 8M
BCDA Yearly EPS VS EstimatesBCDA Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 -5 -10 -15 -20 -25

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for BCDA. In the last year negative earnings were reported.
Also next year BCDA is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
BCDA Price Earnings VS Forward Price EarningsBCDA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
BCDA Per share dataBCDA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -2 -4 -6 -8

4.3 Compensation for Growth

BCDA's earnings are expected to grow with 22.21% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y35.57%
EPS Next 3Y22.21%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for BCDA!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

BIOCARDIA INC

NASDAQ:BCDA (2/21/2025, 8:02:53 PM)

2.31

-0.11 (-4.55%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-13 2024-11-13/amc
Earnings (Next)03-25 2025-03-25/amc
Inst Owners2.72%
Inst Owner Change-69.87%
Ins Owners17.32%
Ins Owner Change1.92%
Market Cap10.58M
Analysts82.5
Price Target15.81 (584.42%)
Short Float %1.37%
Short Ratio1.08
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly Dividend0
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-38%
PT rev (3m)-38%
EPS NQ rev (1m)28.16%
EPS NQ rev (3m)28.16%
EPS NY rev (1m)11.65%
EPS NY rev (3m)38.54%
Revenue NQ rev (1m)12.5%
Revenue NQ rev (3m)-89.77%
Revenue NY rev (1m)-8.5%
Revenue NY rev (3m)-81.7%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 149.01
P/FCF N/A
P/OCF N/A
P/B 3.84
P/tB 3.84
EV/EBITDA N/A
EPS(TTM)-8.25
EYN/A
EPS(NY)-1.34
Fwd EYN/A
FCF(TTM)-1.6
FCFYN/A
OCF(TTM)-1.6
OCFYN/A
SpS0.02
BVpS0.6
TBVpS0.6
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -123.22%
ROE -280.49%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-196.44%
ROA(5y)-168.98%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0.01
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 9.21%
Cap/Sales 9.86%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.78
Quick Ratio 1.78
Altman-Z -37.1
F-Score4
WACC9.44%
ROIC/WACCN/A
Cap/Depr(3y)100.6%
Cap/Depr(5y)96.2%
Cap/Sales(3y)6.49%
Cap/Sales(5y)12.12%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)17.91%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%66.11%
EPS Next Y61.55%
EPS Next 2Y35.57%
EPS Next 3Y22.21%
EPS Next 5Y13.37%
Revenue 1Y (TTM)-87.54%
Revenue growth 3Y47.05%
Revenue growth 5Y-5.41%
Sales Q2Q%-100%
Revenue Next Year-84.28%
Revenue Next 2Y-70.69%
Revenue Next 3Y-55.88%
Revenue Next 5Y70.56%
EBIT growth 1Y38.28%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year26.02%
EBIT Next 3Y0.03%
EBIT Next 5Y-1.61%
FCF growth 1Y31.32%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y30.67%
OCF growth 3YN/A
OCF growth 5YN/A